This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Prothena Announces Research And Development Day And Webcast

DUBLIN, Ireland, Oct. 28, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of a broad range of diseases, today announced that it will host its Research and Development Day on Monday, November 4, 2013 from 9:00 a.m – 12:00 p.m. ET at the New York Palace Hotel in New York, NY.

A live webcast of the conference can be accessed through the investor relations section of the Company's website at . Following the live presentation, a replay of the webcast will be available on the Company's website for 90 days.

Prothena management and scientists will discuss the Company's progress on its lead programs:
  • NEOD001, a monoclonal antibody targeting AL and AA amyloid for the potential treatment of amyloidosis
  • PRX002, a monoclonal antibody targeting alpha-synuclein for the potential treatment of Parkinson's disease
  • PRX003, a monoclonal antibody targeting MCAM (melanoma cell adhesion molecule) for the potential treatment of inflammatory diseases and cancers

Independent subject matter experts will discuss the therapeutic areas of amyloidosis and Parkinson's disease and unmet medical need. 

In addition to Dale Schenk, PhD, President and Chief Executive Officer, Prothena; Gene Kinney, PhD, Chief Scientific Officer and Head of Research & Development, Prothena; Martin Koller, MD, MPH, Chief Medical Officer, Prothena; and Kenneth Flanagan, PhD, Senior Scientist, Prothena, independent participants include:
  • Brian Fiske, PhD, The Michael J. Fox Foundation for Parkinson's Research
  • Eliezer Masliah, MD, Neurology, University of California, San Diego
  • Pat Napoda, Amyloidosis Foundation
  • Ted Yednock, PhD, Scientific Advisor to Prothena, Former EVP and Head of Global Research at Elan Pharmaceuticals (Athena Neurosciences)
  • Jeffrey A. Zonder, MD, Associate Professor of Oncology and Medicine and Leader, Multiple Myeloma Program, Wayne State School of Medicine and Karmanos Cancer Institute

About Prothena

Prothena Corporation plc. is a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of a broad range of diseases that involve protein misfolding and cell adhesion, particularly on the discovery, development and commercialization of potential therapeutic monoclonal antibodies directed specifically to disease-causing proteins. These potential therapies have a broad range of indications, including AL and AA forms of amyloidosis (NEOD001), Parkinson's disease and related synucleinopathies (PRX002), and novel cell adhesion targets involved in inflammatory disease and metastatic cancers (PRX003). For more information, please visit .
CONTACT: Investors:  Tran Nguyen, CFO
         Media:  Anita Kawatra

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.99 -0.02%
FB $99.54 -0.21%
GOOG $678.11 -0.68%
TSLA $148.25 0.18%
YHOO $26.82 -0.85%


Chart of I:DJI
DOW 16,014.38 -12.67 -0.08%
S&P 500 1,852.21 -1.23 -0.07%
NASDAQ 4,268.7630 -14.99 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs